Day 30 SUV(max) predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy

About 70% of patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel) and who achieve a partial response (PR) or stable disease (SD) on the day 30 (D30) positron emission tomography (PET)–computed tomography (CT) scan progress; however, the factors that are p...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Zaki, Ajlan, Feng, Lei, Watson, Grace, Ahmed, Sairah A., Mistry, Haleigh, Nastoupil, Loretta J., Hawkins, Misha, Nair, Ranjit, Iyer, Swaminathan P., Lee, Hun J., Steiner, Raphael E., Flowers, Christopher R., Shpall, Elizabeth J., Kebriaei, Partow, Neelapu, Sattva S., Westin, Jason R., Strati, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092420/
https://www.ncbi.nlm.nih.gov/pubmed/35015825
http://dx.doi.org/10.1182/bloodadvances.2021006715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092420/
https://www.ncbi.nlm.nih.gov/pubmed/35015825
http://dx.doi.org/10.1182/bloodadvances.2021006715

Ejemplares similares